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Abstract
Background: The ICAM-1 gene is a strong positional and biological candidate for susceptibility to
the development of T1D and DN. We have recently demonstrated that SNP rs5498(E469K)
confers susceptibility to the development of T1D and might be associated with DN in Swedish
Caucasians. The present study aimed to further evaluate the association between the ICAM-1
genetic polymorphisms and DN.
Methods:  Two common non-synonymous SNPs, including rs5498(E469K) and
rs1799969(R241G), in the ICAM-1 gene were genotyped in 662 (312 female/350 male) T1D
patients with DN and 620 (369/251) without DN. All patients were selected from the GoKinD
study.
Results: Genotype distributions of both SNPs were in Hardy-Weinberg equilibrium but SNP
rs5498(E469K) had high heterozygous index. In this SNP, the heterozygosity and positivity for the
allele G were found to be significantly associated with DN in female T1D patients (P = 0.010, OR
= 0.633, CI 95% 0.447–0.895 and P = 0.026, OR = 0.692, CI 95% 0.500–0.958). Furthermore, the
female patients without DN carrying three genotypes A/A, A/G and G/G had different cystatin
levels (0.79 ± 0.17, 0.81 ± 0.14 and 0.75 ± 0.12 mg/L, P = 0.021). No significant association of SNP
rs1799969 (R241G) with DN was found.
Conclusion: The present study provides further evidence that SNP rs5498(E469K) in the ICAM-
1 gene presents a high heterozygous index and the allele G of this polymorphism may confers the
decreased risk susceptibility to the development of DN in female T1D patients among the GoKinD
population.
Background
Genome-wide scans and linkage analyses have predicted
that the susceptibility gene(s) for type 1 diabetes (T1D)
and diabetic nephropathy (DN) reside in chromosome
19p13 [1-3]. The intercellular adhesion molecule-1
(ICAM-1) gene is located in this chromosomal region.
ICAM-1 is a 90-kD cell surface glycoprotein of the Ig super
family involved in the firm attachment of leukocytes to
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endothelium [4,5]. Expression of ICAM-1 can be induced
by multiple factors, including inflammatory cytokines,
reactive oxygen species and shear stress [6,7]. Normally,
ICAM-1 is expressed at low levels on the surface of arterial
endothelial cells, but the expression at both mRNA and
protein levels are significantly increased in animal models
of diabetic nephropathy with T1D [7-9] and T2D [10-12].
Furthermore, clinical evidence indicates that the levels of
plasma adhesion molecule are elevated in T1D patients
[13]. Therefore, the ICAM-1 gene is considered as a strong
positional and biological candidate for the susceptibility
to the development of T1D and DN.
In the recent years, several genetic association studies con-
cerning two common non-synonymous SNPs, including
rs5498 E469K(A/G) and rs1799969 R241G(G/A), in the
ICAM-1 gene in T1D patients have been reported. The G
allele of SNP rs5498 E469K(A/G) was preferentially trans-
mitted the affected offspring among Romanian T1D fam-
ilies [14]. This polymorphism was subsequently found to
be associated with adult-onset T1D patients in Japanese
[15]. However, the association of this SNP with T1D was
not detectable in Danish, Finnish and British Caucasians
[16,17]. In another SNP R241G(G/A), transmission of the
allele G was also preferentially transmitted to the affected
offspring among T1D families in Finnish, British, Roma-
nian, European and American Caucasians [18]. We have
recently conducted a genetic association study of five
SNPs in the ICAM-1 gene among Swedish non-diabetic
subjects, T1D patients with and without DN [19]. Data
indicate that SNP rs5498 E469K(A/G) is associated with
T1D in Swedish population. The frequency of the major A
allele of this SNP is increased gradually from non-diabetic
controls, to T1D patients without DN and to the patients
with DN, which suggests that this SNP might be associ-
ated with DN. In order to further evaluate the susceptibil-
ity of the ICAM-1 genetic polymorphisms in the
development of DN, in the present study, we have focused
on genetic association analyses of two common non-syn-
onymous SNPs i.e. rs5498 E469K(A/G) and rs1799969
R241G(G/A) in the ICAM-1 gene by using the well-
selected and characterized cohort of T1D patients with
and without DN from the Genetics of Kidneys in Diabetes
(GoKinD) study [20].
Methods
Clinical material
Clinical material employed in the present study includes
a cohort of 1282 (female 681/male 601) T1D patients.
They were selected from the GoKinD study and collected
by the Juvenile Diabetes Research Foundation in collabo-
ration with the Joslin Diabetes Center and George Wash-
ington University, and the United States Centers for
Diabetes Control and Prevention [20]. The patients with
T1D were diagnosed before age 31 years old and the dura-
tion of T1D is more than 10 years. Medical treatment with
insulin for the patients was instituted within one year of
diagnosis, and was uninterrupted since then.
In total, 620 patients (369/251) without DN were used as
the controls and 662 (312/350) with DN as the cases.
Among the patients, 1177 (91.8%) were of European
descent, while 105 (8.2%) patients were Americans of
Black, Asian, Hispanic or Indian descent. The patients
with DN had T1D for at least 10 years and had persistent
proteinuria or ESRD (not due to condition other than dia-
betes). Persistent proteinuria was defined as 2 out of 3
tests positive for albuminuria (at least 1 month apart), i.e.
dipstick (Albustix or Multistix) at least 1+ or Urine Albu-
min/Urine Creatinine Ratio (ACR) value exceeding 300
μg albumin/mg of urine creatinine. The patients without
DN had persistent normalbuminuria despite duration of
T1D for at least 15 years and had never been treated with
ACE inhibitors. Persistent normoalbuminuria was
defined as at least 2 out 3 of ACR measurements (at least
1 month apart) in random urine specimens being less
than 20 μg albumin/mg of urine creatinine. If 3 ACR
measurements were needed, the highest must also be less
than 40 μg albumin/mg of urine creatinine. ESRD is rec-
ognized as the patients need chronic dialysis or kidney
transplant treatment to maintain their life. The onset of
ESRD is defined as the date of the first dialysis or kidney
transplant, whichever occurred first. Other kidney dis-
eases in cases were excluded [20].
Individuals were excluded from the study if they did not
meet the inclusion criteria just described or if any of the
following exclusion criteria were met: Unable or unwill-
ing to give informed consent; Unable to communicate
with staff; Major psychiatric disorder such as schizophre-
nia; Exclusion in relation to medication: Any antihyper-
tensive medication for controls; Infectious disease: self-
reported HIV positive and active tuberculosis; Pregnant
women (although they may be reconsidered 3 months
after delivery); Other kidney disease due to condition
other than diabetes.
The cases and controls selected from the GoKinD study
were T1D patients with the severity of DN and T1D
patients without DN. T1D patients with micro-albuminu-
ria were not included. The GoKinD study was approved by
the local ethics committees. Material and data transfer
agreement (MTA) was made prior to the present study.
The clinical characteristics of the patients are presented in
Table 1.
SNPs selection and genotyping
In the present study, we selected two non-synonymous
SNPs, rs1799969 R241G and rs5498 E469K(A/G) for gen-
otyping [19]. These two polymorphisms are located,BMC Medical Genetics 2008, 9:47 http://www.biomedcentral.com/1471-2350/9/47
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respectively, in exons 4 and 6 of the ICAM-1 gene. The
SNP ID numbers and detailed sequence information are
available in the public SNP database [21] Genomic DNA
samples were supplied from the GoKinD study. Genotyp-
ing experiments were performed using a high-throughput
SNP scoring technique called dynamic allele specific
hybridization (DASH). PCR-DASH assays and genotyping
protocols are described in our previous report [19].
Statistical analyses
Allele frequency and genotype distribution of the studied
SNPs were tested for Hardy-Weinberg equilibrium
(HWE). For differences between T1D patients with DN
(the cases) and without DN (the controls), two models
were tested comparing either allele frequencies in 2 × 2
contingency tables or genotypes in 3 × 2 contingency
tables. The models were further used for testing either het-
erozygosity (22 vs 12) or allele positivity (11+12 vs 22).
Odds ratios (OR) and 95% confidence intervals (CI) were
calculated to test for relative risk for association. P-values
less than 0.05 were interpreted as statistically significant.
Statistical powers were calculated using software of Pow-
erSampleSize (PS version 2.1.31) [22]. Tests for associa-
tion between genotypes and quantitative traits were
performed using Kruskal-Wallis analysis of ranks for traits
with non-normal distributions, or alternatively, ANOVA
for normally distributed traits. Normal probability plots
were created and parameter distributions were trans-
formed to natural logarithm when needed to improve the
skew-ness and for obtaining a normal distribution before
performing statistical analysis of the relevant phenotypes.
All statistical analyses were performed using Statistica ver-
sion 7.1 (StatSoft Inc. Tulsa, USA) and/or BioMedical
Data Program (BMDP) version 1.12 (Los Angeles, USA).
Results
We have genotyped SNPs rs1799969 R241G and rs5498
E469K in the ICAM-1 gene with the GoKinD material. For
genotyping quality control, DNA samples of the patients
with or without DN were distributed randomly across
plates, and negative controls (water blanks) were included
in each plate. Successful genotype calls in all samples were
≥95%, and the plates were randomly genotyped twice for
duplication. The accuracy was calculated to be 98%. Gen-
otype distribution in both was in HWE (P > 0.05).
We first examined the allelic association of SNPs
rs1799969 R241G and rs5498 E469K in the ICAM-1 gene
with DN in the GoKinD population. The frequencies of
minor alleles in these two polymorphisms were similar
between the groups of T1D patients with and without DN
(Table 2). In SNP rs5498 E469K, the G allele frequency in
the patients without DN was 46.0%, which was not signif-
icantly different from the frequency in the patients with
DN (44.8%, P = 0.554). In SNP rs1799969 R241G, the A
allele frequencies were 11.5% in T1D patients without DN
and 10.3% in the patients with DN (P = 0.325). We fur-
ther analyzed the heterozygosity and allele positivity of
these two SNPs, and found that rs5498 E469K had high
heterozygous index, and the difference of heterozygous
frequencies between T1D patients with and without DN
was borderline significant (P = 0.052). We found that the
frequency of major allele A in female T1D with DN was
similar to the frequency in female patients without DN
(57.2% vs 54.2%, P = 0.265). The association of heterozy-
gosity and allele G positivity between T1D patients with
and without DN in females was found to be significant (P
= 0.010, OR = 0.633, CI 95% 0.447–0.895 and P = 0.026,
OR = 0.692, CI 95% 0.500–0.958, respectively), but not
in males (P = 0.766 and 0.853). In the analyses, statistical
Table 1: Clinical characteristics of T1D patients with and without DN
T1D patients without DN T1D patients with DN
All Male Female All Male Female
N 620 251 369 662 350 312
Age (yrs) 40 ± 8 40 ± 8 40 ± 9 44 ± 7 44 ± 6 43 ± 7
Duration (yrs) 26 ± 8 26 ± 8 26 ± 8 31 ± 8 32 ± 8 31 ± 8
HbA1c (%) 7.48 ± 1.14 7.40 ± 1.14 7.53 ± 1.13 7.40 ± 1.91 7.44 ± 1.74 7.35 ± 2.08
BMI (kg/m2) 26.1 ± 4.3 26.6 ± 3.7 25.6 ± 4.6 25.8 ± 5.4 26.1 ± 4.9 25.5 ± 5.9
Cystatin (mg/L) 0.81 ± 0.14 0.84 ± 0.12 0.79 ± 0.14 2.32 ± 1.77 2.36 ± 1.70 2.27 ± 1.84
Creatinine (mg/dL) 0.90 ± 0.16 0.99 ± 0.14 0.83 ± 0.14 2.19 ± 2.01 2.31 ± 1.96 2.05 ± 2.05
Urine albumin (μg)* 6.7 ± 4.3 6.5 ± 4.3 6.9 ± 4.3 1430 ± 1280 1357 ± 1193 1529 ± 1392
Cholesterol (mg/dL) 185.0 ± 31.5 179.7 ± 30.9 188.8 ± 31.3 186.9 ± 46.1 184.5 ± 46.2 189.7 ± 45.9
HDL (mg/dL) 59.0 ± 15.8 50.9 ± 12.4 64.7 ± 15.4 53.6 ± 17.5 48.9 ± 15.2 58.9 ± 18.5
SBP (mmHg) 118 ± 12 122 ± 12 116 ± 12 132 ± 19 134 ± 18 130 ± 20
DBP (mmHg) 71 ± 8 74 ± 8 70 ± 8 74 ± 11 76 ± 11 72 ± 11
Data are means ± SD. T1D = type 1 diabetic patients and DN = diabetic nephropathy. *Data were calculated from ACR (urine albumin creatinine 
ration) in T1D patients with and without DN. The patients with ESRD were not included.BMC Medical Genetics 2008, 9:47 http://www.biomedcentral.com/1471-2350/9/47
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power was calculated with number of patients, type 1
error probability for a two-sided test, relative risk of the
control treatment relative to the experimental treatment
and ratio of control to experiment patients, and the power
reached to 0.9. In SNP rs1799969 R241G, there was no
high heterozygous index in the genotype distribution.
Analyses of allelic frequencies and genotype distributions
in this polymorphism between the patients with and
without DN in females, males or both sexes were per-
formed and no significant association was found.
We attempted to detect the association between pheno-
types and genotypes of SNP rs5498 E469K in the female
T1D patients without DN or with DN. We found no sig-
nificant difference in clinical features among female T1D
patients with DN carrying three different genotypes,
although the patients with DN and genotype A/G had
slightly increased diastolic blood pressure in comparison
with the patients with homozygous genotypes A/A and G/
G (74 ± 11 vs 71 ± 11, 71 ± 11 mmHg, P = 0.063, Table
3). Among the female T1D patients without DN carrying
genotypes A/A, A/G and G/G, however, there were signif-
icant differences in cystatin levels (0.79 ± 0.17, 0.81 ±
0.14 and 0.75 ± 0.12 mg/L, P = 0.021).
Discussion
In the present study, we have genotyped two non-synony-
mous SNPs rs1799969 R241G and rs5498 E469K in the
ICAM-1 gene in a relatively large cohort from the GoKinD
study. This cohort consists of the cases of T1D patients
with severity of DN and the controls of T1D patients with-
out DN. Data indicated that SNP rs5498 E469K presented
a high heterozygous index in the genotype distribution of
this GoKinD population. The observation is consistent
with the previous and our recent studies in Danish, Finn-
ish, Japanese and Swedish populations (See the summary,
19). Interestingly, we found that the major allele A in SNP
rs5498 E469K was increased from T1D patients without
DN to the patients with DN in females of the GoKinD
population. Further analyses of heterozygosity and allele
positivity indicated that the minor allele G of this SNP was
associated with decreased risk susceptibility to the devel-
opment of DN in female T1D patients. In our previous
study using Swedish material [19], the gradually increas-
ing of the major allele A of this polymorphism from non-
diabetic subjects, to T1D patients without DN and to the
patients with DN was observed. The association between
this polymorphism and DN was not detected most likely
due to limited size of samples.
We have attempted to detect the association of pheno-
types according to the genotypes of this SNP in T1D
patients with DN. We found no significant difference in
clinical features among female T1D patients with DN car-
rying three different genotypes. Among the female
patients without DN, however, the carriers with heterozy-
gosity had significantly increased serum cystatin levels
than the patients with heterozygosity. The data indicate
that the heterozygosity of SNP rs5498 E469K may play a
role in the development of DN. The previous studies dem-
onstrate that the allele A of SNP rs5498 E469K is increased
in T1D patients compared to non-diabetic subjects
[14,15,19]. In the present study, we found that the allele
G of this SNP is associated with the decreased risk suscep-
tibility in female T1D patients with DN. Question con-
cerning the gender specificity of genetic influence of the
ICAM-1 genetic variation is then taken into our consider-
ation. Beyond this study, we have recently studied several
Table 2: Association of SNPs rs1799969 G241R and rs5498 E469K in the ICAM-1 gene between T1D with DN and T1D without DN
SNP ID Position* SNP type Groups Genotypes (%) MAF Heterozygous Allele positivity
rs1799969 Exon 4 R241G T1D without DN AA AG GG
1657594 R = A/G All 10 (1.61) 123 (19.84) 487 (78.55) 0.115
Male 3 (1.20) 52 (20.71) 196 (78.09) 0.116
Female 7 (1.90) 71 (19.24) 291 (78.86) 0.115
T1D with DN
All 3 (0.46) 130 (19.73) 526 (79.81) 0.103 P = 0.877 P = 0.576
Male 1 (0.29) 77 (22.12) 270 (77.59) 0.114 P = 0.721 P = 0.884
Female 2 (0.64) 53 (17.04) 256 (82.32) 0.092 P = 0.413 P = 0.258
rs5498 Exon 6 E469K T1D without DN GG GA AA
1658485 R = A/G All 121 (19.58) 326 (52.75) 171 (27.67) 0.460
Male 50 (20.08)) 130 (52.21) 69 (27.71) 0.462
Female 71 (19.24) 196 (53.12) 102 (27.64) 0.458
T1D with DN
All 141 (21.30) 311 (46.98) 210 (31.72) 0.448 P = 0.052 P = 0.113
Male 75 (21.43) 176 (50.28) 99 (28.29) 0.466 P = 0.766 P = 0.853
Female 66 (21.15) 135 (43.27) 111 (35.58) 0.428 P = 0.010¤ P = 0.026#
*Contig accession number is NT_011295. T1D = type 1 diabetic patients, and DN = diabetic nephropathy. MAF = minor allele frequency.
¤Odd ratio = 0.633 (CI 95% 0.447–0.895); #For the G allele Odd ratio = 0.692 (CI 95% 0.500–0.958).BMC Medical Genetics 2008, 9:47 http://www.biomedcentral.com/1471-2350/9/47
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candidate genes, including NPY and AdipoQ in T1D and
DN, and observed that the genetic polymorphisms in the
NPY and AdipoQ genes are associated with T1D patients
with DN in females but not in males [23,24]. However,
we can't simply make a conclusion because our knowl-
edge needs to be improved based upon accumulation of
evidence from genetic studies and clinical observation in
relation to gender specificity of DN.
rs1799969 R241G(G/A) is another non-synonymous pol-
ymorphism in the ICAM-1 gene and its genotype distribu-
tion has no high heterozygous index in the GoKinD
population. Previous reports demonstrate that the allele G
of this SNP is transmitted in T1D families among Finnish,
British, Romanian, European and American Caucasians
[18]. But, this polymorphism is not associated with DN
among T1D patients in either Swedish [19] or GoKinD
populations. A recent study has indicated that SNP rs5498
E469K but not rs1799969 R241G in the ICAM-1 gene is
associated with the development of differentiation syn-
drome in actue promyelocytic leukemia [25]. Taking
together with our study and the recent report, we suggest
that SNP rs1799969 R241G may not be the major defect
in the development of DN.
Conclusion
In conclusion, we have evaluated the association between
the ICAM-1 genetic polymorphisms and DN with the
material from the GoKinD study and provided evidence
that SNP E469K but not R249G is associated with DN in
T1D. The allele G of SNP E469K in the ICAM-1 gene may
confer the decreased risk susceptibility to the develop-
ment of DN in female T1D patients.
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